Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Core Viewpoint - Eterna Therapeutics Inc. has regained compliance with Nasdaq for continued listing, confirming its market value of at least $35 million, allowing its stock to continue trading on The Nasdaq Stock Market [1]. Group 1: Company Compliance and Financial Status - Eterna received formal confirmation from Nasdaq's Office of General Counsel on November 12, 2024, verifying compliance with the market value of listed securities standard [1]. - The company is now debt-free and operates with a low burn rate, positioning itself as a fully functional preclinical stage cell therapy company [2]. Group 2: Product Development Focus - Eterna is focused on advancing its lead product, ERNA-101, targeting triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer [2][3]. - ERNA-101 is an induced allogenic mesenchymal stem cell product designed to deliver pro-inflammatory cytokines IL-7 and IL-15 to the tumor microenvironment, aiming to enhance anti-tumor immunity [3]. Group 3: Company Overview - Eterna Therapeutics is a publicly traded, preclinical-stage company specializing in innovative off-the-shelf cell therapies for advanced solid tumors, with a primary focus on specific cancer types [3].